SEELOS THERAPEUTICS INC (SEEL) Stock Price, Quote, News and Overview
NASDAQ:SEEL - Nasdaq - US81577F3073 - Common Stock - Currency: USD
SEEL Quote, Performance and Key Statistics
1.28
-1.17 (-47.76%)
The current stock price of SEEL is 1.28 USD. In the past month the price decreased by -64.44%. In the past year, price decreased by -99.83%.
SEEL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About SEEL
Company Profile
Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
Company Info
SEELOS THERAPEUTICS INC
300 Park Avenue, 2nd Floor
New York City NEW YORK 10022 US
CEO: Raj Mehra
Employees: 8
Company Website: https://seelostherapeutics.com/
Phone: 16462932100
SEELOS THERAPEUTICS INC / SEEL FAQ
What is the stock price of SEELOS THERAPEUTICS INC today?
The current stock price of SEEL is 1.28 USD. The price decreased by -47.76% in the last trading session.
What is the ticker symbol for SEELOS THERAPEUTICS INC stock?
The exchange symbol of SEELOS THERAPEUTICS INC is SEEL and it is listed on the Nasdaq exchange.
On which exchange is SEEL stock listed?
SEEL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SEELOS THERAPEUTICS INC stock?
7 analysts have analysed SEEL and the average price target is 122.4 USD. This implies a price increase of 9462.5% is expected in the next year compared to the current price of 1.28. Check the SEELOS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SEELOS THERAPEUTICS INC worth?
SEELOS THERAPEUTICS INC (SEEL) has a market capitalization of 563.20K USD. This makes SEEL a Nano Cap stock.
How many employees does SEELOS THERAPEUTICS INC have?
SEELOS THERAPEUTICS INC (SEEL) currently has 8 employees.
Is SEELOS THERAPEUTICS INC (SEEL) expected to grow?
The Revenue of SEELOS THERAPEUTICS INC (SEEL) is expected to decline by -81.25% in the next year. Check the estimates tab for more information on the SEEL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SEELOS THERAPEUTICS INC (SEEL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SEEL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SEEL, evaluating the profitability, health, valuation and growth aspects
- SEELOS THERAPEUTICS INC (SEEL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SEELOS THERAPEUTICS INC (SEEL) Sales and EPS estimates to see what analysts future expectations are.
- SEELOS THERAPEUTICS INC (SEEL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SEELOS THERAPEUTICS INC (SEEL) Insider and Institutional Ownership to learn about the owners and their transactions.
- SEELOS THERAPEUTICS INC (SEEL) Stock Chart to make your own analysis
- SEELOS THERAPEUTICS INC (SEEL) Latest news and press-releases to stay up to date.
Does SEELOS THERAPEUTICS INC (SEEL) stock pay dividends?
SEEL does not pay a dividend.
When does SEELOS THERAPEUTICS INC (SEEL) report earnings?
SEELOS THERAPEUTICS INC (SEEL) will report earnings on 2024-11-12, before the market open.
What is the Price/Earnings (PE) ratio of SEELOS THERAPEUTICS INC (SEEL)?
SEELOS THERAPEUTICS INC (SEEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-45.32).
SEEL Technical Analysis
SEEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SEEL. Both the profitability and financial health of SEEL have multiple concerns.
SEEL Financial Highlights
Over the last trailing twelve months SEEL reported a non-GAAP Earnings per Share(EPS) of -45.32. The EPS decreased by -318.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 203.13% | ||
| ROA | 171.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SEEL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to SEEL. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 97.05% and a revenue growth -81.25% for SEEL